Prostamax peptide: what the Khavinson prostate tetrapeptide is, what little has been studied and what is unknown

Prostamax is the trade name for the tetrapeptide Lys-Glu-Asp-Pro: lysine, glutamic acid, aspartic acid and proline in that order, written KEDP in single-letter code, so the KEDP peptide and prostamax are the same molecule. It was designed by Vladimir Khavinson’s group at the St Petersburg Institute of Bioregulation and Gerontology using the method behind their whole series: analyse the amino acid composition of a polypeptide extract of an organ, then synthesise a very short peptide meant to reproduce that organ’s tissue-specific activity ^{[7] [9]}. For prostamax the organ is the prostate, and the parent extract is the prostate preparation the group calls Prostatilen, which has its own clinical history in Russia as an injectable and suppository product ^{[7] [8]}.

It is important to keep the two apart. Prostatilen is a mixture of peptides extracted from bull prostate; prostamax is a single synthetic four-amino-acid peptide. The developers’ 2013 review of clinical results for their peptide bioregulators lists Prostatilen among the preparations with clinical studies, and does not list prostamax ^[8]. Sellers sometimes describe the prostamax bioregulator as the tested prostate peptide, borrowing the extract’s record; the prostamax prostatilen distinction is the first thing a buyer should understand.

Prostamax shares its first three residues with vesugen (Lys-Glu-Asp), pancragen (Lys-Glu-Asp-Trp), testagen (Lys-Glu-Asp-Gly) and livagen (Lys-Glu-Asp-Ala). The proline at the fourth position is the only thing that distinguishes it, and proline at a C-terminus tends to protect a peptide from carboxypeptidases, which may be why it was chosen. Every paper on prostamax comes from the developers’ network or from a collaborating group in Tbilisi that publishes in Georgian Medical News and Biofizika; nothing independent exists.

The developers’ explanation for all their short peptides is that they enter the nucleus and change gene activity by altering chromatin. Prostamax is one of the peptides that theory was built on. In a 2004 comparison of five short peptides (vilon, epitalon, livagen, prostamax and cortagen) in leukocytes from people aged 75 to 88, all five activated ribosomal genes and loosened densely packed chromatin, and epitalon, livagen and prostamax also decondensed the pericentromeric structural heterochromatin of chromosome 1 ^[1]. The same year, a microcalorimetry study of human lymphocytes reported that prostamax shifted two of the heat-absorption peaks of chromatin denaturation to lower temperatures by 2.9 and 1.0 degrees, which the authors interpreted as partial relaxation of the 30-nanometre chromatin fibre into the 10-nanometre filament ^[2].

A 2012 study from the Tbilisi group treated lymphocytes from people aged 75 to 86 with prostamax and reported that the frequency of sister chromatid exchanges roughly doubled, from 5.9 to 12.0 per cell, that silver-staining nucleolar organiser regions rose from 0.95 to 2.5 per cell, and that large blocks of pericentromeric heterochromatin on chromosomes 1 and 9 became less frequent; they concluded that prostamax decondenses chromatin in old age and releases genes repressed by heterochromatinisation ^[5]. A 2009 study from the same group used microcalorimetry to look at prostamax together with copper and cadmium ions in cultured lymphocytes from ageing donors, and reported that copper condensed heterochromatin while cadmium decondensed and partly denatured it; the abstract does not describe a separate prostamax effect ^[4].

A 2023 modelling study found that KEDP and KEDG were among the short peptides with the highest predicted binding to the intestinal amino acid and peptide transporters LAT1, LAT2 and PEPT1, which the developers proposed as the route by which such peptides could be absorbed after oral dosing ^[6]. This is a docking calculation, not a measurement.

Two points about the chromatin evidence deserve emphasis. First, these are laboratory treatments of blood cells in a dish, not of the people who donated them, and no study has looked at prostate cells. Second, a doubling of sister chromatid exchanges is usually read by geneticists as a marker of DNA damage or genotoxic stress, not as a benefit. The Tbilisi authors present it as evidence of chromatin activation; an independent reader might see it as a safety signal. No study has resolved which it is.

The single tissue result is from 2006. Zakutskii and colleagues cultured explants of heart, lung, prostate and pancreas from three-week-old and 18-month-old rats and added cardiogen, bronchogen, prostamax or pancragen at 0.05 ng/mL. Each peptide stimulated growth in the culture of its own organ compared with untreated explants, in both young and old rats, and the authors suggested the peptides could be used clinically to stimulate repair in the corresponding tissue during ageing ^[3]. That is the whole of the prostate-specific evidence: one organ-culture experiment, reported in an abstract without numbers, in which prostamax stimulated the outgrowth of rat prostate explants.

There is no study of prostamax in any model of prostate disease. We found no study in benign prostatic hyperplasia, prostatitis, prostate cancer or lower urinary tract symptoms in any species, and no measurement of prostate size, PSA, testosterone, dihydrotestosterone, urine flow or inflammation after prostamax. The prostamax prostate claims that appear on seller pages, that it supports prostate health, reduces inflammation or improves urinary symptoms, do not correspond to any published experiment on this peptide. Where a seller cites a clinical study, it is almost always a study of Prostatilen, the extract, or of a different peptide altogether.

The chromatin studies are the only other body of work ^{[1] [2] [5]}, and as described above they concern blood cells from elderly donors, not the prostate. Nothing links them to any prostate outcome. The developers’ 2002 overview mentions clinical trials of the peptide preparation obtained from the prostate, meaning the extract, but says nothing of the tetrapeptide ^[7].

We found no study in which prostamax was given to a person, no case series and no registered clinical trial; there is no prostamax entry on ClinicalTrials.gov as of September 2026. The human material in the literature is lymphocytes from donors aged 75 to 88, treated in the laboratory ^{[1] [2] [4] [5]}. The developers themselves do not claim clinical studies of prostamax in their review of clinical results ^[8].

This makes prostamax, together with testagen, the least-studied peptide in the Khavinson series and one of the least-studied products sold by research peptide stores at all. Pancragen has monkeys and one human report; vesugen has three small human reports; vilon has decades of Russian clinical use. Prostamax has a single rat organ-culture result and some chromatin assays. Anyone using it for the prostate is relying on the name.

No study has measured onset or duration of any effect in any living animal or person. The organ-culture result was read after days in culture ^[3], and the chromatin assays were done on cells cultured with the peptide for the usual two to three days ^[5]. Any claim about how many weeks prostamax takes to work is unsupported.

The only concentration reported for prostamax is 0.05 ng/mL, the amount that stimulated rat prostate explants in culture ^[3]. No animal has been given prostamax by any route in a published study, so there is no dose per kilogram, and no human dose exists. This is stated for completeness; it is not a recommendation.

Research suppliers sell prostamax as a lyophilised powder, usually in 10 to 20 mg vials, and Russian supplement versions are sold as capsules; neither amount derives from a dose-finding study, because none has been done. For converting vial contents to a concentration for a laboratory protocol, use the peptide calculator or the prostamax calculator page.

No route of administration has been studied for prostamax in a living animal. The developers’ transporter modelling suggests KEDP is a good ligand for intestinal peptide transporters ^[6], and its C-terminal proline may resist digestive carboxypeptidases, but no pharmacokinetic study has measured prostamax in blood or prostate tissue after oral, subcutaneous or any other dosing. The related peptide livagen was shown to resist intestinal peptidases in rats; that result belongs to livagen and does not transfer.

At about 487.5 g/mol, prostamax is the heaviest of the KED-family tetrapeptides apart from pancragen, and a certificate of analysis should show that mass. Because it shares its first three residues with four other cheap peptides, HPLC purity alone cannot confirm identity; only mass spectrometry can.

No safety study of prostamax exists in any species and there is no human data at all. The ordinary questions, whether it affects PSA, testosterone, urinary symptoms or interacts with alpha-blockers or 5-alpha-reductase inhibitors, have no answers because nothing has been measured.

One published finding deserves to be read as a caution rather than a benefit. In lymphocytes from elderly donors, prostamax doubled the frequency of sister chromatid exchanges ^[5]. Sister chromatid exchange assays are a standard genotoxicity screen, and an agent that doubles the rate would normally be flagged for further testing. The authors interpret the change as chromatin activation, consistent with their theory, but no mutagenicity, clastogenicity or carcinogenicity study has been done to settle it. A second theoretical concern is that a peptide credited with stimulating growth of prostate tissue ^[3] has never been examined for its effect on prostate cells that are already growing abnormally, as in benign hyperplasia or cancer. Prostamax is not on the FDA’s compounding list of substances that may present significant safety risks ^[10], which reflects only that nobody nominated it.

Prostamax is not an approved medicine in the UK, US, EU, Canada or Australia. A product marketed for human use with claims about the prostate or urinary symptoms would be treated as a medicine in the UK regardless of a research-use label, and the MHRA has licensed no such product. In the US it is not an FDA-approved drug and has not appeared on the compounding category 2 list ^[10]. In Russia it is sold as a dietary supplement rather than a registered medicine, which confers no status elsewhere; the extract Prostatilen is a separate product with its own Russian registration. We have not confirmed prostamax’s standing under the WADA Prohibited List.

For the rules on buying and holding research peptides in your country, see the legal status overview, the UK page, the US page and the Australia page.

Prostamax is supplied as a freeze-dried powder. It contains no cysteine, methionine or tryptophan and should be reasonably stable, but the general rules apply: keep the sealed vial cold, dry and away from light, refrigerate any reconstituted solution and use it within a limited period. See how to store peptides and the bacteriostatic water guide.

A four-amino-acid peptide costs little to make, so price per milligram says nothing about quality. Compare prostamax prices across the stores we track, including UK listings and US listings. Read how to read a peptide COA first and check that the measured mass is about 487.5 g/mol. Our third-party tested suppliers list shows which stores publish independent tests, and the third-party testing guide explains what those tests do and do not prove.

Sellers often place prostamax alongside testagen and gonadorelin as men’s health peptides, or with the other Khavinson peptides such as thymalin and pinealon. Gonadorelin is a licensed hormone with real human data; prostamax is not comparable. For a general orientation, see what research peptides are and how to spot a fake peptide supplier.